Effects of nintedanib in patients with IPF: subgroup analysis by Charlson Comorbidity Index (CCI)

E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen, Germany), E. Bargagli (Siena, Italy), F. Caro (Buenos Aires, Argentina), M. Glassberg (Miami, FL, United States of America), B. Schinzel (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia)

Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Session: What is hot in idiopathic pulmonary fibrosis?
Session type: E-poster session
Number: 1789
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen, Germany), E. Bargagli (Siena, Italy), F. Caro (Buenos Aires, Argentina), M. Glassberg (Miami, FL, United States of America), B. Schinzel (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia). Effects of nintedanib in patients with IPF: subgroup analysis by Charlson Comorbidity Index (CCI). 1789

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: